Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by bigdaddydeesteron Feb 22, 2018 5:09pm

269 Views

Post# 27605318

We should be getting positive results

I see no reason why there won't positive results in the phase 2B clinical trials, I mean all research to date has basically proven that ATB-346 has gastrointestinal-sparing effects. I've done my DD, the only question is: how will the market react to positive news?

https://www.antibethera.com/wordpress/wp-content/uploads/2017/07/Antioxid-Redox-Signal.-2017-May-15-1.pdf

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!